Taiwan's 2-in-1 Screening Program for Gastric and Colorectal Cancer Shows Significant Benefits

A study led by National Taiwan University Hospital (NTUH), published in *JAMA*, indicates that integrating a one-time *H. pylori* stool antigen test into Taiwan's existing colorectal cancer screening program could substantially reduce gastric cancer deaths and generate societal benefits five times greater than the cost. Taiwan became the first country globally to offer this combined screening nationwide for individuals aged 45-74, starting January 1, 2026. The approach involves using the same stool sample to screen for both colorectal cancer and *Helicobacter pylori* infection, the primary cause of gastric cancer.

Context

Gastric cancer is a leading cause of cancer-related deaths, particularly in East Asia, where *Helicobacter pylori* infection is prevalent. Taiwan's National Health Insurance has been proactive in cancer screening, and this new program builds on existing efforts to combat colorectal cancer. The integration of *H. pylori* testing into the screening process is a pioneering step that could set a precedent for other countries.

Why it matters

Taiwan's innovative screening program addresses two major health concerns simultaneously, potentially saving lives and reducing healthcare costs. By targeting both gastric and colorectal cancers, it represents a significant advancement in preventive healthcare. The program's societal benefits outweigh its costs, highlighting the value of investing in public health initiatives.

Implications

If successful, the program could lead to a significant decrease in gastric cancer mortality rates in Taiwan. It may also influence other countries to adopt similar dual screening strategies, potentially improving global cancer prevention efforts. Additionally, the program could reshape healthcare resource allocation, emphasizing preventive care over treatment.

What to watch

The rollout of the combined screening program is set to begin on January 1, 2026, and its implementation will be closely monitored for effectiveness. Health authorities will likely track participation rates and health outcomes to assess the program's impact. Stakeholder reactions, including those from healthcare providers and patients, will also be important indicators of the program's acceptance.